Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Accenture
Colorcon
Chubb
Johnson and Johnson
AstraZeneca
Cipla
US Department of Justice
Boehringer Ingelheim

Generated: December 10, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AMPICILLIN AND SULBACTAM

« Back to Dashboard

Clinical Trials for Ampicillin And Sulbactam

Trial ID Title Status Sponsor Phase Summary
NCT00044746 Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 4 Phase IV Open-Label Foot Infection Study is being conducted to generate comparative Efficacy and Safety data in Diabetic Inpatients.
NCT00137007 Zithromax EV in Community-Acquired Pneumonia (CAP) Completed Pfizer Phase 4 The intravenous (IV) regimen containing azithromycin (Zithromax) plus ampicillin-sulbactam is consistent with current guidelines for the treatment of CAP. In fact the International guidelines for the treatment of CAP in hospitalised patients suggests the use of a combination between a b-lactam and a macrolide. This trial will allow investigators to evaluate the efficacy of azithromycin plus ampicillin-sulbactam in the treatment of hospitalized subjects with community acquired pneumonia. In addition, this trial will allow investigators to evaluate the safety and toleration of combination therapy.
NCT00356148 The Efficacy of Prophylactic Antibiotic Administration During Breast Cancer Surgery in Overweight Patients. Completed Marmara University Phase 4 This is a single center trial to compare the rate of surgical site infection (SSI) in normal (BMI equal to or less than 25; Control Group)) and overweight (BMI over 25) women who are undergoing breast cancer surgery. The overweight patients are further randomized into two groups; in one group patients receive prophylactic antibiotics (ampicillin/sulbactam; Prophylaxis Group), in the other they do not (No Prophylaxis Group).
NCT00368537 Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin Infections Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 4 The purpose of this study is to compare the safety and efficacy of the antibiotic tigecycline with other antibiotics, ampicillin-sulbactam, and amoxicillin-clavulanate in the treatment of a complicated skin and/or skin structure infection (cSSSI).
NCT00630513 T.E.A. Study Three Days Ertapenem Versus Three Days Ampicillin- Sulbactam Completed St. Orsola Hospital Phase 4 The aim of the study was to compare the activity (efficacy and safety) of Ertapenem administered according to a short treatment for three days versus a short treatment for three days with AS in patients with an community acquired IAI of mild to moderate severity.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Ampicillin And Sulbactam

Condition Name

Condition Name for Ampicillin And Sulbactam
Intervention Trials
Lung Abscess 2
Intra-Abdominal Infection 2
Pneumonia 2
Skin Diseases, Bacterial 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ampicillin And Sulbactam
Intervention Trials
Pneumonia 5
Infection 4
Communicable Diseases 2
Surgical Wound Infection 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ampicillin And Sulbactam

Trials by Country

Trials by Country for Ampicillin And Sulbactam
Location Trials
United States 20
Japan 15
Germany 10
Canada 4
Korea, Republic of 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ampicillin And Sulbactam
Location Trials
California 2
Ohio 2
New Jersey 1
New York 1
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ampicillin And Sulbactam

Clinical Trial Phase

Clinical Trial Phase for Ampicillin And Sulbactam
Clinical Trial Phase Trials
Phase 4 10
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ampicillin And Sulbactam
Clinical Trial Phase Trials
Completed 10
Active, not recruiting 2
Recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ampicillin And Sulbactam

Sponsor Name

Sponsor Name for Ampicillin And Sulbactam
Sponsor Trials
Pfizer 3
Wyeth is now a wholly owned subsidiary of Pfizer 2
St. Orsola Hospital 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ampicillin And Sulbactam
Sponsor Trials
Other 11
Industry 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
McKesson
Cantor Fitzgerald
Healthtrust
Harvard Business School
Cerilliant
Johnson and Johnson
Citi
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.